Journal article

FIRST‐LINE IBRUTINIB VENETOCLAX TREATMENT FOR MANTLE CELL LYMPHOMA IN OLDER PATIENTS OR THOSE WITH TP53 MUTATION: A NEW OPEN‐LABEL ARM OF THE PHASE 3 PCYC‐1143 SYMPATICO STUDY